JP2018507235A5 - - Google Patents

Download PDF

Info

Publication number
JP2018507235A5
JP2018507235A5 JP2017546186A JP2017546186A JP2018507235A5 JP 2018507235 A5 JP2018507235 A5 JP 2018507235A5 JP 2017546186 A JP2017546186 A JP 2017546186A JP 2017546186 A JP2017546186 A JP 2017546186A JP 2018507235 A5 JP2018507235 A5 JP 2018507235A5
Authority
JP
Japan
Prior art keywords
thiophen
piperidin
tert
methanone
butylpyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017546186A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018507235A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/020802 external-priority patent/WO2016141258A1/en
Publication of JP2018507235A publication Critical patent/JP2018507235A/ja
Publication of JP2018507235A5 publication Critical patent/JP2018507235A5/ja
Withdrawn legal-status Critical Current

Links

JP2017546186A 2015-03-04 2016-03-04 ステロール調節エレメント結合タンパク質(srebp)阻害剤 Withdrawn JP2018507235A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN615DE2015 2015-03-04
IN615/DEL/2015 2015-03-04
IN640/DEL/2015 2015-03-09
IN640DE2015 2015-03-09
PCT/US2016/020802 WO2016141258A1 (en) 2015-03-04 2016-03-04 Sterol regulatory element-binding proteins (srebps) inhibitors

Publications (2)

Publication Number Publication Date
JP2018507235A JP2018507235A (ja) 2018-03-15
JP2018507235A5 true JP2018507235A5 (cg-RX-API-DMAC7.html) 2019-04-18

Family

ID=55586426

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017546186A Withdrawn JP2018507235A (ja) 2015-03-04 2016-03-04 ステロール調節エレメント結合タンパク質(srebp)阻害剤

Country Status (5)

Country Link
US (1) US10189826B2 (cg-RX-API-DMAC7.html)
EP (1) EP3265457A1 (cg-RX-API-DMAC7.html)
JP (1) JP2018507235A (cg-RX-API-DMAC7.html)
CA (1) CA2977539A1 (cg-RX-API-DMAC7.html)
WO (1) WO2016141258A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016105491A1 (en) 2014-12-23 2016-06-30 Fgh Biotech Compositions of fatostatin based heterocyclic compounds and uses thereof
US10183015B2 (en) 2015-03-04 2019-01-22 Medivation Technologies Llc Heterocyclic compounds and methods of use
KR102498741B1 (ko) 2016-04-29 2023-02-10 에프지에이치 바이오테크 인코포레이티드 질환 치료용 이-치환된 피라졸 화합물
EP3510027B1 (en) 2016-09-07 2022-11-02 FGH BioTech, Inc. Di-substituted pyrazole compounds for the treatment of diseases
CA3089134A1 (en) 2018-01-29 2019-08-01 Capulus Therapeutics, Llc Srebp inhibitors comprising a 6-membered central ring
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2020132700A1 (en) 2018-12-21 2020-06-25 Fgh Biotech Inc. Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof
CN113631163A (zh) * 2019-01-28 2021-11-09 卡普勒斯疗法有限责任公司 包括噻吩中心环的srebp抑制剂
WO2021097122A1 (en) * 2019-11-13 2021-05-20 Capulus Therapeutics, Llc Srebp inhibitor comprising a thiophene central ring
JP2023502603A (ja) * 2019-11-13 2023-01-25 カピュラス セラピューティクス リミテッド ライアビリティ カンパニー 環状アミドを有するチオフェン化合物およびそれらの使用
WO2021154735A1 (en) * 2020-01-27 2021-08-05 Capulus Therapeutics, Llc Srebp inhibitors comprising a thiophene central ring
EP4185584A1 (en) * 2020-07-24 2023-05-31 Capulus Therapeutics, LLC Srebp inhibitors comprising a thiophene central ring
CN112225728A (zh) * 2020-08-18 2021-01-15 四川农业大学 一种多取代苯甲酰胺化合物及其制备方法和应用
CN117050074B (zh) * 2022-05-05 2025-08-12 中国药科大学 一类吡啶联咪唑并吡啶化合物及其制备方法与用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96891A0 (en) * 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
US6291514B1 (en) 1998-02-09 2001-09-18 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
AU765072B2 (en) 1998-02-09 2003-09-11 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines as protease inhibitors, in particular as urokinase inhibitors
ATE303364T1 (de) 1999-12-16 2005-09-15 Schering Corp Substituierte imidazole als neuropeptide y y5 rezeptor antagonisten
AR029686A1 (es) 2000-06-22 2003-07-10 Dow Agrosciences Llc Compuestos de 2-(3,5-disustituido-4-piridil)-4-(tienilo, tiazolilo o arilfenil)-1,3-oxazolina, composiciones y metodos para el control de insectos o acaros y/o plantas utilizando dichos compuestos
BRPI0410348A (pt) 2003-05-14 2006-05-30 Torreypines Therapeutics Inc compostos e usos dos mesmos na modulação de amilóide-beta
EP1893591A1 (en) * 2005-06-08 2008-03-05 Novartis AG POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS
MX2007015729A (es) 2005-06-09 2008-02-21 Schering Plough Ltd Control de parasitos en animales con derivados de n-[(feniloxi)fenil]-1,1,1-trifluorometansulfonamida y de n[(fenilsulfanil)fenil]-1,1,1-trifluorometansulfonamida.
KR101370280B1 (ko) 2005-07-26 2014-03-06 바이알 - 포르텔라 앤드 씨에이 에스에이 Comt 억제제로서의 니트로카테콜 유도체
JP5261176B2 (ja) 2005-08-16 2013-08-14 アイカジェン, インコーポレイテッド 電位作動型ナトリウムチャンネル阻害剤
US8229106B2 (en) 2007-01-22 2012-07-24 D.S.P. Group, Ltd. Apparatus and methods for enhancement of speech
US8207196B2 (en) 2007-02-02 2012-06-26 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
US9212179B2 (en) 2007-02-02 2015-12-15 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
US9187485B2 (en) 2007-02-02 2015-11-17 Baylor College Of Medicine Methods and compositions for the treatment of cancer and related hyperproliferative disorders
AU2008227979B2 (en) * 2007-03-16 2014-02-06 Actelion Pharmaceuticals Ltd Amino- pyridine derivatives as S1P1 /EDG1 receptor agonists
KR20100110834A (ko) 2007-12-21 2010-10-13 메르크 세로노 에스. 에이. 트리아졸 옥사다이아졸 유도체
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
WO2011085269A1 (en) 2010-01-08 2011-07-14 Selexagen Therapeutics, Inc. Raf kinase inhibitors
WO2012084678A1 (en) 2010-12-23 2012-06-28 Syngenta Participations Ag Novel imidazoles useful as plant fungicides
JP2014062047A (ja) 2011-01-21 2014-04-10 Taisho Pharmaceutical Co Ltd ピラゾール誘導体
GB201116017D0 (en) 2011-09-16 2011-10-26 Univ Surrey Bi-aromatic and tri-aromatic compounds as nadph oxidase inhibitors
EP2793879A4 (en) 2011-12-23 2015-07-01 Millennium Pharm Inc HETEROARYLE AND USES THEREOF
WO2013110007A1 (en) 2012-01-18 2013-07-25 The Trustees Of Columbia University In The City Of New York USE OF FATOSTATIN FOR TREATING CANCER HAVING A p53 MUTATION
WO2014199164A1 (en) 2013-06-12 2014-12-18 Ampla Pharmaceuticals, Inc. Diaryl substituted heteroaromatic compounds
CA2916648A1 (en) 2013-06-26 2014-12-31 Rett Syndrome Research Trust Rett syndrome and treatments therefore
TR201809185T4 (tr) 2013-08-28 2018-07-23 Medivation Tech Llc Heterosiklik bileşikler ve kullanım yöntemleri.
US10183015B2 (en) 2015-03-04 2019-01-22 Medivation Technologies Llc Heterocyclic compounds and methods of use

Similar Documents

Publication Publication Date Title
JP2018507235A5 (cg-RX-API-DMAC7.html)
RU2396269C2 (ru) Производные гетероарилзамещенного пиперидина в качестве ингибиторов печеночной карнитин пальмитоилтрансферазы (l-cpt1)
RU2457207C2 (ru) Активаторы глюкокиназы
HRP20231310T1 (hr) Heteroarilaminopirimidin amidni inhibitori autofagije i postupci njihove primjene
JP5864589B2 (ja) 細菌トポイソメラーゼii阻害性2−エチルカルバモイルアミノ−1,3−ベンゾチアゾール−5−イル類
US20120101100A1 (en) Heterocyclic urea derivatives and methods of use thereof-211
KR101949624B1 (ko) Tank-결합 키나제 억제제 화합물로서 유용한 아미노트리아진 유도체
HRP20230244T1 (hr) Derivati 3-(1-oksoizoindolin-2-il)piperidin-2,6-diona i njihova upotreba
JP2016523911A5 (cg-RX-API-DMAC7.html)
JP2020530446A5 (cg-RX-API-DMAC7.html)
SI3177619T1 (en) 2- (morpholin-4-yl) -1,7-naphthyridines
TWI628174B (zh) 新穎吡啶衍生物
JP2015510938A5 (cg-RX-API-DMAC7.html)
JP2015522002A5 (cg-RX-API-DMAC7.html)
IL258577A (en) 2,4-dihydroxy-nicotinamides as apj agonists
JP2014525448A5 (cg-RX-API-DMAC7.html)
JP2017530960A5 (cg-RX-API-DMAC7.html)
EP1756076A1 (en) Hetroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
JPWO2020231808A5 (cg-RX-API-DMAC7.html)
WO2016046530A1 (en) Novel compounds
RU2010137300A (ru) Модуляторы бета-амилоида
JP2008513500A5 (cg-RX-API-DMAC7.html)
JP2018530591A5 (cg-RX-API-DMAC7.html)
JP2011503194A5 (cg-RX-API-DMAC7.html)
JP2016500073A5 (cg-RX-API-DMAC7.html)